We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+31.45%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$854M
AUM Growth
+$40.2M
Cap. Flow
-$21.9M
Cap. Flow %
-2.56%
Top 10 Hldgs %
56.07%
Holding
53
New
14
Increased
5
Reduced
13
Closed
13

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$39.7M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$14.6M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$13.8M
4
COGT icon
Cogent Biosciences
COGT
+$13.6M
5
ATXS
Astria Therapeutics
ATXS
+$8.92M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$25.8M
2
VTYX
Ventyx Biosciences
VTYX
+$21.9M
3
BCYC
Bicycle Therapeutics
BCYC
+$15.2M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$15.1M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLU
51
DELISTED
BELLUS Health Inc.
BLU
– –
-800,000
Closed -$8.45M
TCDA
52
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-950,000
Closed -$9.96M
TCDA
53
PUT
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-240,200
Closed -$2.52M
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2022 Portfolio in Review

As of Q4 2022, Logos Global Management held 53 positions worth $854M, up 4.9% from $813M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Logos Global Management's Q4 2022 filing shows 14 new, 5 increased, 13 reduced and 13 closed positions. Its largest new stake was Immunovant: 3,150,000 shares worth $55.9M. The largest sale was Ascendis Pharma A/S, an estimated $25.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Logos Global Management's largest Q4 2022 buy was Immunovant: 3,150,000 shares worth $55.9M.
  • Logos Global Management added most to Xenon Pharmaceuticals in Q4 2022, an estimated $14.6M increase.
  • Logos Global Management's biggest Q4 2022 reduction was Ventyx Biosciences, cutting an estimated $21.9M.
  • Logos Global Management fully exited Ascendis Pharma A/S in Q4 2022, selling an estimated $25.8M.
  • Logos Global Management's ten largest holdings make up 56% of its $854M portfolio in Q4 2022.
  • Logos Global Management opened 14 new positions and closed 13 in Q4 2022.
  • Logos Global Management's portfolio value rose 4.9% quarter-over-quarter to $854M.

Based on Logos Global Management's 13F filing for Q4 2022, filed 14 Feb 2023.